

1705

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		Docket Number: 1662/568077	
Application Number 10/661,259	Filing Date September 12, 2003	Examiner Not Yet Assigned	Art Unit 1625
Invention Title POLYMORPHS OF FEXOFENADINE HYDROCHLORIDE		Inventors DOLITZKY, et al.	

Address to:
Mail Stop:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop: _____
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
on

Date: 3/17/2005

Signature: Agnes Xu
Agnes Xu

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 35 U.S.C. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. In accordance with the Official Gazette of August 5, 2003, which stated that the United States Patent and Trademark Office waived the requirement under 37 C.F.R. § 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. patent applications filed after June 30, 2003, copies of each of the cited U.S. patents and U.S. patent application publications are not being provided.
3. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
4. Applicant's attorney certifies that each item of information contained in the information disclosure statement was first cited in the European Search Report (copy attached) from European Patent Office in a counterpart foreign application.

5. The Commissioner is hereby authorized to charge payment of the 37 C.F.R. § 1.17(p) (submission of an Information Disclosure Statement under §1.97(c)) fee of \$180.00 and any additional fees that may be required to the deposit account of **Kenyon & Kenyon**, deposit account number **11-0600**. A copy of this communication is enclosed for charging purposes.


Dated: *march 17, 05*

By:

Payam Moradian

Payam Moradian (Reg. No. 52,048)

KENYON & KENYON
One Broadway
New York, New York 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)
CUSTOMER NUMBER 26646



INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449	ATTY. DOCKET NO. 1662/568077	SERIAL NO. 10/661,259
	APPLICANT Dolitzky, et al.	
	FILING DATE September 12, 2003	GROUP 1625

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 03/084510 A	October 16, 2003	PCT				
	WO 02/102777 A	December 27, 2002	PCT				
	WO 03/011295 A	February 13, 2003	PCT				

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	